vectra felis
ceva santé animale - piriproksifēnu, dinotefuran - pretparazītu izstrādājumi, insekticīdi un repelenti, citi ectoparasiticides lokālai lietošanai, piriproksifēnu, kombinācijas - kaķi - Ārstēšana un profilakse blusu invāzijas (ctenocephalides felis) par kaķiem. vienu pieteikumu novērš blusu invāzijas par vienu mēnesi. tas arī novērš to vairošanos blusas, inhibējot blusu rašanos vidē, cat 3 mēnešiem.
bovigen scour
forte healthcare limited, Īrija - inaktivēta liellopu rota vīruss, celms tm-91, serotips g6p1, inaktivēta liellopu coronavirus celma c-197, un inaktivētu escherichia coli celms ek/17 paužot f5 (k99) adhesin - emulsija injekcijām - liellopi
felisecto plus
zoetis belgium sa - selamectin, sarolaner - antiparazītu līdzekļi, insekticīdi un repelentu līdzekļi - kaķi - par kaķiem, vai risks, sajauc parazītu invāzijas, ērces un blusas, utis, ērces, kuņģa-zarnu trakta nematodes vai heartworm. veterinārās zāles tiek norādītas vienīgi tad, ja tās lieto pret ērcēm, un vienlaikus tiek norādīts viens vai vairāki citi mērķa parazīti.
kolibin rc neo emulsija injekcijām
bioveta, a.s., Čehija - inaktivēta e. coli baktērijas,inaktivēta liellopu coronavirus celma c-197,inaktivēta liellopu rota vīruss, celms tm-91 - emulsija injekcijām - liellopi
doxyvit 100 100 mg/g pulveris iekšķīgi lietojama šķīduma pagatavošanai
ceva sante animale., francija - doksiciklīna hidrohlorīds - pulveris iekšķīgi lietojama šķīduma pagatavošanai - 100 mg/g - cūkas; tītari; vistas; zosis
enroxil
krka, d.d., novo mesto, slovēnija - enrofloxacin - premikss ārstnieciskās barības pagatavošanai - 5/100 g/g - cūkas; mājputni
clopidogrel acino
acino ag - clopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antitrombotiskie līdzekļi - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.
clopidogrel taw pharma (previously clopidogrel mylan)
taw pharma (ireland) limited - klopidogrela hidrohlorīds - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotiskie līdzekļi - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.
clopidogrel teva generics b.v.
teva pharma b.v. - clopidogrel (as hydrochloride) - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antitrombotiskie līdzekļi - klopidogrelu, ir norādīts pieaugušajiem, lai novērstu atherothrombotic notikumi:pacientiem, kas cieš no miokarda infarkta (no dažām dienām līdz mazāk nekā 35 dienas), išēmisko insultu (7 dienas līdz mazāk nekā 6 mēnešus) vai izveidota, perifēro artēriju slimība. patients suffering from acute coronary syndrome:non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st segmenta pacēlums, akūts miokarda infarkts, kopā ar asa, medicīniski ārstēti pacienti saņemt trombolītiskā terapija. sīkāku informāciju, lūdzu, skatiet sadaļā 5.
clopidogrel/acetylsalicylic acid zentiva (previously duocover)
sanofi-aventis groupe - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - antitrombotiskie līdzekļi - akūtu koronāro syndromemyocardial infarkts.